Professional Documents
Culture Documents
0.40 A
0.25
0.20
0.15
0.1 0.2 0.4 0.8 1.6
Total IgG (µg/ml)
0.35
Discussion
Most patients who develop C diYcile diarrhoea
respond promptly to either oral metronidazole
or vancomycin.1 26 Diarrhoea may recur when
these agents are discontinued but even then
almost always resolves quickly when antimicro-
bial therapy is resumed. Persisting diarrhoea
despite appropriate treatment with metronida-
zole and vancomycin, as occurred in both
Figure 2: Plain abdominal radiograph of patient 2 patients in this report, is unusual. Both patients
showing colonic dilatation and thickening of the colonic also had severe colitis as evidenced by pseu-
wall consistent with notable mucosal oedema (A).
Photomicrograph of sigmoidoscopic biopsy specimen domembrane formation, thickening of the
showing acutely inflamed colonic mucosa and an overlying colonic wall, abdominal tenderness, and ab-
pseudomembrane (B). dominal distension. Severe, unresponsive pseu-
domembranous colitis may result in colonic
perforation, septicaemia, and death.1 27–30
levels is presented in fig 3B (this particular Colectomy may be life saving in these circum-
preparation is identified by an arrow in fig 3A). stances. However, many patients are consid-
All preparations contained IgG against both C ered unfit for colectomy because of advanced
age and severe coexisting medical problems.
diYcile toxin A and toxin B as measured by
Even those who are considered fit to undergo
ELISA.
colectomy for severe pseudomembranous coli-
Finally, we determined whether pooled tis have a mortality rate of approximately
human immunoglobulin was capable of neu- 50%.27–30 Thus it was felt that intravenous
tralising the cytotoxic eVects of C diYcile immunoglobulin treatment for unresponsive
toxins. All nine preparations neutralised C dif- pseudomembranous colitis was justified for the
ficile culture filtrate cytotoxicity at IgG concen- two patients presented in this report. In both
trations of 0.4–1.6 mg/ml. Control serum from instances there was rapid clinical improvement
a healthy volunteer who lacked specific anti- immediately following immunoglobulin ad-
bodies against C diYcile toxin A or toxin B ministration.
failed to neutralise the cytotoxicity of C diYcile Both patients in this report had recognised
culture filtrate in this assay. risk factors for C diYcile colitis including anti-
Intravenous IgG for C diYcile colitis 369
biotic treatment, admission to hospital, ad- acutely ill patients with severe colitis who are
vanced age, malignancy, and recent major often elderly and debilitated and already
surgery.1 2 27 31 32 The elderly and those who receiving multiple medications. A controlled
experience major surgery or trauma are known prospective study would be needed to examine
to have impaired antibody responses against a properly the eYcacy of immunoglobulin in
range of antigens and this may include reduced these circumstances. However, the uncommon
C diYcile antitoxin production.14 16 33 34 Neither and urgent nature of this condition makes such
patient had received cytotoxic chemotherapy at a study logistically diYcult. The two cases
the time of onset of diarrhoea but the first reported here suggest that passive immuno-
patient had a lymphoma which may also be therapy with pooled normal human immu-
associated with diminished antibody produc- noglobulin may be a useful addition to metro-
tion in response to antigenic challenge. nidazole and vancomycin and may hasten
A number of previous studies have reported recovery or avert colectomy in patients with
low serum antibody levels against C diYcile severe, refractory pseudomembranous colitis.
toxins in patients with severe and prolonged C
diYcile colitis.14 18–23 Elderly individuals, who
are most likely to develop C diYcile diarrhoea,
may also have lower levels of neutralising anti- 1 Kelly CP, Pothoulakis C, LaMont JT. Clostridium diYcile
colitis. N Engl J Med 1994; 330: 257–62.
toxin in their serum.16 If inadequate antibody 2 McFarland LV, Mulligan ME, Kwok RY, Stamm WE.
production does indeed contribute to more Nosocomial acquisition of Clostridium diYcile infection.
N Engl J Med 1989; 320: 204–10.
severe or more prolonged disease, intravenous 3 Bongaerts GP, Lyerly DM. Role of toxins A and B in the
administration of preformed antitoxin may be pathogenesis of Clostridium diYcile disease. Microb Pathog
1994; 17: 1–12.
beneficial. Passive immunotherapy, either oral 4 Lyerly DM, Krivan HC, Wilkins TD. Clostridium diYcile:
or parenteral, is eVective in preventing C its disease and toxins. Clin Microbiol Rev 1988; 1: 1–18.
diYcile enterocolitis in animals but little 5 Lyerly DM, Lockwood DE, Richardson SH, Wilkins TD.
Biological activities of toxins A and B of Clostridium diY-
information is available for humans.14 24 35–37 cile. Infect Immun 1982; 35: 1147–50.
The largest study to date is our report of 6 Riegler M, Sedivy R, Pothoulakis C, Hamilton G, Zacherl J,
Bischof G, et al. Clostridium diYcile toxin B is more potent
intravenous immunoglobulin administration to than toxin A in damaging human colonic epithelium in
children with recurrent C diYcile vitro. J Clin Invest 1995; 95: 2004–11.
7 Triadafilopoulos G, Pothoulakis C, O’Brien MJ, LaMont
diarrhoea.21 38 39 In that study we demonstrated JT. DiVerential eVects of Clostridium diYcile toxins A and
a notable increase in serum antitoxin A levels B on rabbit ileum. Gastroenterology 1987; 93: 273–9.
8 Dove CH, Wang SZ, Price SB, Phelps CJ, Lyerly DM,
following immunoglobulin administration. In Wilkins TD, et al. Molecular characterization of the
this study both patients were treated urgently Clostridium diYcile toxin A gene. Infect Immun 1990; 58:
480–8.
with immunoglobulin and, unfortunately, 9 Kelly CP, Becker S, Linevsky JK, Joshi MA, O’Keane JC,
serum was not saved to allow measurement of Dickey BF, et al. Neutrophil recruitment in Clostridium
diYcile toxin A enteritis in the rabbit. J Clin Invest 1994;
their serum antitoxin antibody levels. 93: 1257–65.
As C diYcile colitis is toxin mediated we 10 Triadafilopoulos G, Pothoulakis C, Weiss R, Giampaolo C,
LaMont JT. Comparative study of Clostridium diYcile
assume that the immunoglobulin acts by bind- toxin A and cholera toxin in rabbit ileum. Gastroenterology
ing and neutralising C diYcile toxins. The 1989; 97: 1186–92.
intravenous administration of 150 mg/kg of 11 von Eichel-Streiber C, Laufenberg-Feldmann R, Sartingen
S, Schulze J, Sauerborn M. Cloning of Clostridium difficile
immunoglobulin results in serum IgG levels of toxin B gene and demonstration of high N-terminal
greater than 5 mg/ml whereas toxin neutralis- homology between toxin A and B. Med Microbiol Immunol
(Berl) 1990; 179: 271–9.
ing activity is evident in vitro at IgG concentra- 12 Just I, Selzer J, Wilm M, von Eichel-Streiber C, Mann M,
tions of approximately 1 mg/ml.40 Thus neu- Aktories K. Glucosylation of Rho proteins by Clostridium
diYcile toxin B. Nature 1995; 375: 500–3.
tralising levels of IgG against C diYcile toxins 13 Just I, Wilm M, Selzer J, Rex G, von Eichel-Streiber C,
are readily achieved in the blood following Mann M, et al. The enterotoxin from Clostridium diYcile
(ToxA) monoglucosylates the Rho proteins. J Biol Chem
immunoglobulin infusion. However, the pre- 1995; 270: 13932–6.
cise mechanism of action of intravenous 14 Kelly CP. Immune response to Clostridium diYcile. Eur J
Gastroenterol Hepatol 1996; 8: 1048–53.
immunoglobulin is still not entirely clear since, 15 Kelly CP, Pothoulakis C, Orellana J, LaMont JT. Human
to be eVective, IgG antitoxin must leave the colonic aspirates containing immunoglobulin A antibody to
Clostridium diYcile toxin A inhibit toxin A-receptor bind-
circulation and bind to toxins A and B within ing. Gastroenterology 1992; 102: 35–40.
the colonic lamina propria or intestinal 16 Nakamura S, Mikawa M, Nakashio S, Takabatake M,
Okado I, Yamakawa K, et al. Isolation of Clostridium diY-
lumen.9 14 41 This may occur as a result of the cile from the feces and the antibody in sera of young and
exudation of serum proteins across an inflamed elderly adults. Microbiol Immunol 1981; 25: 345–51.
17 Viscidi R, Laughon BE, Yolken R, Bo-Linn P, Moench T,
colonic mucosa. Ryder RW, et al. Serum antibody response to toxins A and
Our first patient had a recurrence of C diY- B of Clostridium diYcile. J Infect Dis 1983; 148: 93–100.
18 Aronsson B, Granstrom M, Mollby R, Nord CE. Serum
cile diarrhoea four weeks after immunoglobulin antibody response to Clostridium diYcile toxins in patients
infusion. This may simply be the result of dis- with Clostridium diYcile diarrhoea. Infection 1985; 13:
97–101.
continuing metronidazole and vancomycin 19 Aronsson B, Granstrom M, Mollby R, Nord CE. Enzyme-
three weeks earlier. However, the timing of her linked immunosorbent assay (ELISA) for antibodies to
Clostridium diYcile toxins in patients with pseudomem-
relapse is also consistent with the expected branous colitis and antibiotic-associated diarrhoea. J
time course of degradation of intravenously Immunol Methods 1983; 60: 341–50.
20 Bacon AE III, Fekety R. Immunoglobulin G directed
administered human IgG.40 against toxins A and B of Clostridium diYcile in the
The animal and human studies discussed general population and patients with antibiotic-associated
diarrhoea. Diagn Microbiol Infect Dis 1994; 18: 205–9.
earlier indicate that normal pooled human 21 Leung DY, Kelly CP, Boguniewicz M, Pothoulakis C, LaM-
immunoglobulin is a rational therapy for severe ont JT, Flores A. Treatment with intravenously adminis-
tered gammaglobulin of chronic relapsing colitis induced
C diYcile colitis particularly in cases where by Clostridium diYcile toxin. J Pediatr 1991; 118: 633–7.
standard antimicrobial agents prove ineffective. 22 Mulligan ME, Miller SD, McFarland LV, Fung HC, Kwok
RY. Elevated levels of serum immunoglobulins in asympto-
Immunoglobulin treatment carries some risks matic carriers of Clostridium diYcile. Clin Infect Dis 1993;
but these are relatively small in the context of 16 (suppl 4): S239–44.
370 Salcedo, Keates, Pothoulakis, Warny, Castagliuolo, LaMont, et al
23 Warny M, Vaerman JP, Avesani V, Delmee M. Human anti- 34 Weksler ME. Immune senescence. Ann Neurol 1994; 35
body response to Clostridium diYcile toxin A in relation to (suppl): S35–7.
clinical course of infection. Infect Immun 1994; 62: 384–9. 35 Corthier G, Muller MC, Wilkins TD, Lyerly D, L’Haridon
24 Kelly CP, Pothoulakis C, Vavva F, Castagliuolo I, Bostwick R. Protection against experimental pseudomembranous
EF, O’Keane JC, et al. Anti-Clostridium diYcile bovine colitis in gnotobiotic mice by use of monoclonal antibodies
immunoglobulin concentrate inhibits cytotoxicity and against Clostridium diYcile toxin A. Infect Immun 1991;
enterotoxicity of C. diYcile toxins. Antimicrob Agents 59: 1192–5.
Chemother 1996; 40: 373–9.
25 Pothoulakis C, Barone LM, Ely R, Faris B, Clark ME, 36 Kim PH, Iaconis JP, Rolfe RD. Immunization of adult ham-
Franzblau C, et al. Purification and properties of Clostrid- sters against Clostridium diYcile-associated ileocecitis and
ium diYcile cytotoxin B. J Biol Chem 1986; 261: 1316–21. transfer of protection to infant hamsters. Infect Immun
26 Kelly CP, LaMont JT. Treatment of Clostridium diYcile 1987; 55: 2984–92.
diarrhoea and colitis. In: Wolfe MM, ed. Gastrointestinal 37 Lyerly DM, Bostwick EF, Binion SB, Wilkins TD. Passive
pharmacotherapy. Philadelphia: WB Saunders, 1993; 199– immunization of hamsters against disease caused by
212. Clostridium diYcile by use of bovine immunoglobulin G
27 Medich DS, Lee KK, Simmons RL, Grubbs PE, Yang HC, concentrate. Infect Immun 1991; 59: 2215–8.
Showalter DP. Laparotomy for fulminant pseudomembra- 38 Tjellstrom B, Stenhammar L, Eriksson S, Magnusson KE.
nous colitis. Arch Surg 1992; 127: 847–52. Oral immunoglobulin A supplement in treatment of
28 Morris LL, Villalba MR, Glover JL. Management of Clostridium diYcile enteritis [letter]. Lancet 1993; 341:
pseudomembranous colitis. Am Surg 1994; 60: 548–51. 701–2.
29 Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium 39 Hassett J, Meyers S, McFarland L, Mulligan ME. Recurrent
diYcile colitis. Dis Colon Rectum 1995; 38: 350–4. Clostridium diYcile infection in a patient with selective
30 Trudel JL, Deschenes M, Mayrand S, Barkun AN. Toxic IgG1 deficiency treated with intravenous immune globulin
megacolon complicating pseudomembranous enterocolitis. and Saccharomyces boulardii. Clin Infect Dis 1995; 20
Dis Colon Rectum 1995; 38: 1033–8.
31 Bender BS, Bennett R, Laughon BE, Greenough WB III, (suppl 2): S266–8.
Gaydos C, Sears SD, et al. Is Clostridium diYcile endemic 40 Pirofsky B, Campbell SM, Montanaro A. Individual patient
in chronic-care facilities? Lancet 1986; ii: 11–3. variations in the kinetics of intravenous immune globulin
32 McFarland LV. Epidemiology of infectious and iatrogenic administration. J Clin Immunol 1982; 2: 7S-14S.
nosocomial diarrhoea in a cohort of general medicine 41 Pothoulakis C, LaMont JT, Eglow R, Gao N, Rubins JB,
patients. Am J Infect Control 1995; 23: 295–305. Theoharides TC, et al. Characterization of rabbit ileal
33 Schwab R, Walters CA, Weksler ME. Host defense mecha- receptors for Clostridium diYcile toxin A. Evidence for a
nisms and aging. Semin Oncol 1989; 16: 20–7. receptor-coupled G protein. J Clin Invest 1991; 88: 119–25.